001     906021
005     20230113085400.0
024 7 _ |a 10.3233/JAD-210261
|2 doi
024 7 _ |a 1387-2877
|2 ISSN
024 7 _ |a 1875-8908
|2 ISSN
024 7 _ |a 2128/33066
|2 Handle
024 7 _ |a 35068451
|2 pmid
024 7 _ |a WOS:000768536700025
|2 WOS
037 _ _ |a FZJ-2022-01186
082 _ _ |a 610
100 1 _ |a Richter, Nils
|0 P:(DE-Juel1)167565
|b 0
|e Corresponding author
|u fzj
245 _ _ |a Age and Anterior Basal Forebrain Volume Predict the Cholinergic Deficit in Patients with Mild Cognitive Impairment due to Alzheimer’s Disease
260 _ _ |a Amsterdam
|c 2022
|b IOS Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1670921060_17645
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Abstract.Background: Early and severe neuronal loss in the cholinergic basal forebrain is observed in Alzheimer’s disease (AD). Todate, cholinomimetics play a central role in the symptomatic treatment of AD dementia. Although basic research indicatesthat a cholinergic deficit is present in AD before dementia, the efficacy of cholinomimetics in mild cognitive impairment(MCI) remains controversial. Predictors of cholinergic impairment could guide individualized therapy.Objective: To investigate if the extent of the cholinergic deficit, measured using positron emission tomography (PET) and thetracer 11C-N-methyl-4-piperidyl acetate (MP4A), could be predicted from the volume of cholinergic basal forebrain nucleiin non-demented AD patients.Methods: Seventeen patients with a high likelihood of MCI due to AD and 18 age-matched cognitively healthy adultsunderwent MRI-scanning. Basal forebrain volume was assessed using voxel-based morphometry and a cytoarchitectonicatlas of cholinergic nuclei. Cortical acetylcholinesterase (AChE) activity was measured using MP4A-PET.Results: Cortical AChE activity and nucleus basalis of Meynert (Ch4 area) volume were significantly decreased in MCI.The extent of the cholinergic deficit varied considerably across patients. Greater volumes of anterior basal forebrain nuclei(Ch1/2 area) and younger age (Spearman’s rho(17) = –0.596, 95%-CI [–0.905, –0.119] and 0.593, 95%-CI [0.092, 0.863]))were associated with a greater cholinergic deficit.Conclusion: Data suggest that less atrophy of the Ch1/2 area and younger age are associated with a more significant cholinergicdeficit in MCI due to AD. Further investigations are warranted to determine if the individual response to cholinomimeticscan be inferred from these measures.Keywords: Acetylcholinesterase, aging, MP4A, nucleus basalis of Meynert, positron emission tomography
536 _ _ |a 5251 - Multilevel Brain Organization and Variability (POF4-525)
|0 G:(DE-HGF)POF4-5251
|c POF4-525
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de
700 1 _ |a David, Lara-Sophia
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Grothe, Michel J.
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Teipel, Stefan
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Dietlein, Markus
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Tittgemeyer, Marc
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Neumaier, Bernd
|0 P:(DE-Juel1)166419
|b 6
|u fzj
700 1 _ |a Fink, Gereon R.
|0 P:(DE-Juel1)131720
|b 7
|u fzj
700 1 _ |a Onur, Oezguer A.
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Kukolja, Juraj
|0 P:(DE-Juel1)131730
|b 9
773 _ _ |a 10.3233/JAD-210261
|g p. 1 - 16
|0 PERI:(DE-600)2070772-1
|n 1
|p 425-440
|t Journal of Alzheimer's disease
|v 86
|y 2022
|x 1387-2877
856 4 _ |u https://juser.fz-juelich.de/record/906021/files/Invoice_P20220240.pdf
856 4 _ |y OpenAccess
|u https://juser.fz-juelich.de/record/906021/files/POSTPRINT.pdf
856 4 _ |y Restricted
|u https://juser.fz-juelich.de/record/906021/files/jad_2022_86-1_jad-86-1-jad210261_jad-86-jad210261.pdf
909 C O |o oai:juser.fz-juelich.de:906021
|p openaire
|p open_access
|p OpenAPC
|p driver
|p VDB
|p openCost
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 0
|6 P:(DE-Juel1)167565
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 6
|6 P:(DE-Juel1)166419
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 7
|6 P:(DE-Juel1)131720
913 1 _ |a DE-HGF
|b Key Technologies
|l Natural, Artificial and Cognitive Information Processing
|1 G:(DE-HGF)POF4-520
|0 G:(DE-HGF)POF4-525
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-500
|4 G:(DE-HGF)POF
|v Decoding Brain Organization and Dysfunction
|9 G:(DE-HGF)POF4-5251
|x 0
914 1 _ |y 2022
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-18
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J ALZHEIMERS DIS : 2021
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-18
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-18
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2022-11-18
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-18
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-3-20090406
|k INM-3
|l Kognitive Neurowissenschaften
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)INM-3-20090406
980 _ _ |a APC
980 1 _ |a APC
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21